AU622630B2 - D-cycloserine and its prodrugs as cognitive enhancers - Google Patents

D-cycloserine and its prodrugs as cognitive enhancers Download PDF

Info

Publication number
AU622630B2
AU622630B2 AU26319/88A AU2631988A AU622630B2 AU 622630 B2 AU622630 B2 AU 622630B2 AU 26319/88 A AU26319/88 A AU 26319/88A AU 2631988 A AU2631988 A AU 2631988A AU 622630 B2 AU622630 B2 AU 622630B2
Authority
AU
Australia
Prior art keywords
hydrido
acceptable salt
dosage form
pharmaceutically
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26319/88A
Other languages
English (en)
Other versions
AU2631988A (en
Inventor
Alex A. Cordi
Gail E. Handelmann
Joseph B. Monahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of AU2631988A publication Critical patent/AU2631988A/en
Application granted granted Critical
Publication of AU622630B2 publication Critical patent/AU622630B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU26319/88A 1987-12-01 1988-11-29 D-cycloserine and its prodrugs as cognitive enhancers Ceased AU622630B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US127121 1987-12-01
US07/127,121 US4904681A (en) 1987-12-01 1987-12-01 D-cycloserine and its prodrugs as cognitive enhancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU10839/92A Division AU1083992A (en) 1987-12-01 1992-02-10 Formulations of d-cycloserine as cognitive enhancers

Publications (2)

Publication Number Publication Date
AU2631988A AU2631988A (en) 1989-06-01
AU622630B2 true AU622630B2 (en) 1992-04-16

Family

ID=22428413

Family Applications (4)

Application Number Title Priority Date Filing Date
AU26319/88A Ceased AU622630B2 (en) 1987-12-01 1988-11-29 D-cycloserine and its prodrugs as cognitive enhancers
AU28130/89A Abandoned AU2813089A (en) 1987-12-01 1988-12-01 Use of a glycine b partial agonist for memory and learning enhancement or treatment of a cognitive disorder
AU10839/92A Abandoned AU1083992A (en) 1987-12-01 1992-02-10 Formulations of d-cycloserine as cognitive enhancers
AU77467/94A Abandoned AU7746794A (en) 1987-12-01 1994-10-26 Formulations of D-cycloserine as cognitive enhancers

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU28130/89A Abandoned AU2813089A (en) 1987-12-01 1988-12-01 Use of a glycine b partial agonist for memory and learning enhancement or treatment of a cognitive disorder
AU10839/92A Abandoned AU1083992A (en) 1987-12-01 1992-02-10 Formulations of d-cycloserine as cognitive enhancers
AU77467/94A Abandoned AU7746794A (en) 1987-12-01 1994-10-26 Formulations of D-cycloserine as cognitive enhancers

Country Status (20)

Country Link
US (1) US4904681A (enExample)
EP (2) EP0319824B1 (enExample)
JP (2) JPH0621065B2 (enExample)
KR (1) KR0134198B1 (enExample)
AT (1) ATE68698T1 (enExample)
AU (4) AU622630B2 (enExample)
CA (1) CA1328617C (enExample)
DE (1) DE3865817D1 (enExample)
DK (1) DK173589B1 (enExample)
ES (1) ES2040314T3 (enExample)
FI (1) FI885559A0 (enExample)
GR (1) GR3003571T3 (enExample)
IE (1) IE61825B1 (enExample)
IL (1) IL88531A (enExample)
NO (1) NO885337D0 (enExample)
NZ (1) NZ227131A (enExample)
PH (1) PH26467A (enExample)
PT (1) PT89109B (enExample)
WO (1) WO1989005144A1 (enExample)
ZA (1) ZA888981B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5066665A (en) * 1990-05-21 1991-11-19 Warner-Lambert Co. Substituted isoxazolidin-3-ones and derivatives thereof acting at muscarinic receptors
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
NZ260302A (en) * 1994-04-13 1996-05-28 New Zealand Meat Ind Res Inst Treating bait aversion by including substances which disrupt the associative learning process into bait compositions
AU4128896A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
AU4019395A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
FR2742748B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveau derive de 4-imidazolidinone, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR100396114B1 (ko) * 1996-10-31 2003-11-20 동아제약 주식회사 D-시클로세린의 제조방법
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
EP1084704B1 (en) * 1998-06-10 2006-03-29 Meiji Seika Kaisha Ltd. Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20060252761A1 (en) * 2001-03-29 2006-11-09 Michael Davis Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
ATE519485T1 (de) * 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
CN1527813A (zh) 2001-04-02 2004-09-08 О 作为治疗剂的抗氧化剂硝基氧和亚硝氮碳基
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
UA80055C2 (en) * 2003-05-27 2007-08-10 Forest Laboratories Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment
EP1660634A4 (en) * 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
SG10201501050RA (en) 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP6419087B2 (ja) 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201505937SA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2019527235A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109890825B (zh) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung

Also Published As

Publication number Publication date
JPH0621065B2 (ja) 1994-03-23
DK669088D0 (da) 1988-11-30
IL88531A0 (en) 1989-06-30
IE883567L (en) 1989-06-01
PT89109B (pt) 1993-07-30
ES2040314T3 (es) 1995-04-01
EP0319824B1 (en) 1991-10-23
EP0421997A1 (en) 1991-04-17
WO1989005144A1 (en) 1989-06-15
AU2631988A (en) 1989-06-01
FI885559A0 (fi) 1988-11-30
JPH05201859A (ja) 1993-08-10
KR890009392A (ko) 1989-08-01
DE3865817D1 (enExample) 1991-11-28
IE61825B1 (en) 1994-11-30
ATE68698T1 (de) 1991-11-15
ZA888981B (en) 1990-01-31
AU7746794A (en) 1995-01-05
KR0134198B1 (ko) 1998-04-21
DK669088A (da) 1989-06-02
PH26467A (en) 1992-07-27
NZ227131A (en) 1991-09-25
CA1328617C (en) 1994-04-19
AU1083992A (en) 1992-05-07
US4904681A (en) 1990-02-27
JPH01193220A (ja) 1989-08-03
PT89109A (pt) 1989-12-29
IL88531A (en) 1993-02-21
GR3003571T3 (enExample) 1993-03-16
NO885337D0 (no) 1988-11-30
AU2813089A (en) 1989-07-05
EP0319824A1 (en) 1989-06-14
DK173589B1 (da) 2001-04-02

Similar Documents

Publication Publication Date Title
US4904681A (en) D-cycloserine and its prodrugs as cognitive enhancers
EP0387867B1 (en) Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
AU679492B2 (en) Methods for the improvement of cognition with functional antagonists of the glycine NMDA receptor complex
US5260324A (en) Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5187171A (en) Use of a glycine b partial agonist as an antipsychotic
US5468763A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5087633A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US6656962B2 (en) Use of amino-isoxazolidone compounds for improvement of lexical priming
US5866597A (en) Use of triazine compounds for the treatment of memory and learning disorders
AP478A (en) Use of triazine compounds for the treatment of impaired memory and learning disorders.
US20030073730A1 (en) Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury